MP14-10 PERIOPERATIVE OUTCOMES OF NEPHRECTOMY FOLLOWING IMMUNE CHECKPOINT INHIBITOR THERAPY: A MULTICENTER COLLABORATIVE STUDY

INTRODUCTION AND OBJECTIVE:Immune checkpoint inhibitors (ICI) are gaining acceptance in the management of metastatic renal cell carcinoma (mRCC) with four FDA approved regimens to date. However, da...